Product Information
TALICIA DR 10-250-12.5 MG CAP is a brand product labeled by RedHill Biopharma Ltd, priced at $4.8825 per EA under NDC 57841115002. Its NADAC has been published 290 times since Mar 17, 2021.
FDA first approved this application on Nov 1, 2019.
Strength
250; 10; 12.5 mg/1; mg/1; mg/1
Manufacturer
RedHill Biopharma LtdNDC
57841115002
Classification
Brand
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTINApproval Type
New Drug (NDA)
FDA Application
NDA213004FDA Approved
11/1/2019
On Market Since
3/9/2020
Pharmacological Classes
Price Statistics
The NADAC for TALICIA DR 10-250-12.5 MG CAP has been published 290 times since Mar 17, 2021, and over the history we have for it it has risen 29.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.8825 per EA |
|---|---|
| All-time high | $4.8866 (Aug 12, 2026) |
| All-time low | $3.7817 (Mar 17, 2021) |
| 52-week high | $4.8866 |
| 52-week low | $4.7590 |
| Median price | $4.3661 |
| Average price | $4.4078 |
| Largest weekly change | +8.0% (Jan 4, 2023) |
| Weeks tracked | 290 |
| Tracking since | Mar 17, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the omeprazole magnesium, amoxicillin and rifabutin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
RedHill Biopharma Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
omeprazole magnesium, amoxicillin and rifabutin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Penicillin-class Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TALICIA DR 10-250-12.5 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for TALICIA DR 10-250-12.5 MG CAP, manufactured by RedHill Biopharma Ltd, is $4.8825 per EA (NDC 57841115002), effective Sep 30, 2026.
How has the price of TALICIA DR 10-250-12.5 MG CAP changed over time?
Over the history we have for it, the NADAC for TALICIA DR 10-250-12.5 MG CAP has risen 29.1%. It has been tracked across 290 weekly CMS publications since Mar 17, 2021.
What are the highest and lowest recorded NADAC prices for TALICIA DR 10-250-12.5 MG CAP?
Since Mar 17, 2021, the NADAC for TALICIA DR 10-250-12.5 MG CAP has ranged from a low of $3.7817 (Mar 17, 2021) to a high of $4.8866 (Aug 12, 2026), with a median of $4.3661 per EA.
Are there cheaper alternatives to TALICIA DR 10-250-12.5 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of TALICIA DR 10-250-12.5 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TALICIA DR 10-250-12.5 MG CAP?
TALICIA DR 10-250-12.5 MG CAP (NDC 57841115002) is labeled by RedHill Biopharma Ltd, and CMS classifies it as a brand product.